Connect with us

Politics

Calamos Advisors Boosts Stake in Silicon Laboratories to $1.02 Million

editorial

Published

on

Calamos Advisors LLC significantly increased its investment in Silicon Laboratories, Inc. (NASDAQ:SLAB) during the second quarter of 2023, raising its stake by 77.3%. According to the firm’s recent filing with the Securities and Exchange Commission, Calamos now holds 6,917 shares of the semiconductor company, valued at approximately $1.02 million following the acquisition of an additional 3,015 shares during the quarter.

This strategic move by Calamos is part of a broader trend among institutional investors adjusting their portfolios in relation to Silicon Laboratories. For instance, Envestnet Asset Management Inc. increased its holdings by 5.0% in the first quarter, now owning 111,129 shares worth around $12.51 million. Cerity Partners LLC also expanded its position by 5.9%, bringing its total to 13,552 shares valued at $1.53 million.

Additionally, the Louisiana State Employees Retirement System raised its stake by 1.1%, now holding 9,100 shares worth $1.02 million, while Securian Asset Management Inc. increased its position by 4.2% with 2,498 shares valued at $281,000. Edgestream Partners L.P. also made headlines by acquiring a new stake valued at approximately $325,000.

Analysts Weigh In on Silicon Laboratories

Analysts have recently issued a range of price targets for Silicon Laboratories. Weiss Ratings maintained a “sell (e+)” rating in a report on Thursday, while Stifel Nicolaus revised their target from $144.00 to $160.00, assigning a “buy” rating. Conversely, Morgan Stanley lowered its target from $157.00 to $144.00, recommending an “equal weight” rating.

Barclays also adjusted their price objective, increasing it from $100.00 to $130.00 and maintaining an “equal weight” rating. Following suit, Susquehanna raised its target from $110.00 to $150.00, giving the stock a “neutral” rating. Currently, four analysts have rated the stock as a buy, three as hold, and one as sell, resulting in an average rating of “hold” and a consensus price target of $153.43, according to MarketBeat.com.

Current Stock Performance and Earnings Report

On Friday, shares of Silicon Laboratories opened at $121.89. The company has experienced a 12-month low of $82.82 and a high of $160.00, with a market capitalization of $4 billion and a price-to-earnings ratio of -37.85. The company’s 50-day moving average price stands at $132.36, while the 200-day moving average is $132.70.

Silicon Laboratories reported its quarterly earnings results on November 4, 2023, revealing earnings per share of $0.32, surpassing analysts’ expectations of $0.30 by $0.02. The company achieved revenue of $206 million, slightly exceeding consensus estimates of $205.04 million. Despite this positive performance, Silicon Laboratories reported a negative net margin of 14.88% and a negative return on equity of 7.21%. For the fourth quarter of 2025, Silicon Laboratories has projected earnings per share guidance in the range of $0.400 to $0.700.

In terms of insider trading, Senior Vice President Brandon Tolany sold 1,800 shares of Silicon Laboratories on August 29, 2023, at an average price of $133.57, amounting to a total of $240,426. Following this transaction, he retains 62,328 shares, valued at approximately $8.33 million. Over the past 90 days, insiders have sold 12,070 shares valued at $1.70 million, while company insiders maintain ownership of 1.60% of the company’s stock.

Silicon Laboratories, a fabless semiconductor company, specializes in analog-intensive mixed-signal solutions across various sectors, including the Internet of Things (IoT), smart cities, commercial applications, and connected health.

Continue Reading

Trending

Copyright © All rights reserved. This website offers general news and educational content for informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the information provided. The content should not be considered professional advice of any kind. Readers are encouraged to verify facts and consult relevant experts when necessary. We are not responsible for any loss or inconvenience resulting from the use of the information on this site.